[Drug induced angioedema (ACE-inhibitors and other)]

Presse Med. 2015 Jan;44(1):43-7. doi: 10.1016/j.lpm.2014.07.019. Epub 2014 Dec 12.
[Article in French]

Abstract

Angiotensin Converting Enzyme inhibitors (ACE-I) use is a frequent cause of AE and must be suspected systematically in all patients with AE. The risk of AE is increased in: black people, transplanted patients, those who take gliptins or immunosuppressants (mTOR i). Angiotensin converting enzyme inhibitors induced angioedema (ACE-I AE) can occur a few days to several years after the beginning of this treatment and persist a few months after stopping it. ACE-I AE affect mainly the face and particularly the tongue but also the abdomen. ACE-I AE can be life threatening, due to the involvement of the tongue and the larynx. ACE-I AE must be treated as in the hereditary form when life threatening signs are present, with icatibant or C1 inhibitor concentrate. AE can occur in 10% of angiotensin receptor blockers (ARBs) treated patients who had developed ACE-I AE.

Publication types

  • Review

MeSH terms

  • Angioedema / chemically induced*
  • Angioedema / diagnosis
  • Angioedema / epidemiology
  • Angioedema / therapy
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Bradykinin / adverse effects
  • Contraindications
  • Dipeptidyl-Peptidase IV Inhibitors / adverse effects
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Immunosuppressive Agents / adverse effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Dipeptidyl-Peptidase IV Inhibitors
  • Fibrinolytic Agents
  • Immunosuppressive Agents
  • Bradykinin